DnB Asset Management
PTGX icon

DnB Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

DnB Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$316K Hold
2,244
– – ﹤0.01% 951
2026
Q2 		$275K Hold
2,244
– – ﹤0.01% 1047
2026
Q1 		$237K Buy
+2,244
New +$199K ﹤0.01% 1080

Other funds holding PTGX

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return

DnB Asset Management's PTGX Position: Q3 2026 in Review

DnB Asset Management held its Protagonist Therapeutics (PTGX) position steady in Q3 2026 at 2,244 shares worth $316K. The position accounts for ﹤0.01% of the portfolio, ranked #951.

DnB Asset Management first reported a position in PTGX in Q1 2026 and has held it in 3 quarters since. 252 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • DnB Asset Management held 2,244 shares of Protagonist Therapeutics worth $316K as of Q3 2026.
  • DnB Asset Management left its Protagonist Therapeutics share count unchanged in Q3 2026.
  • Protagonist Therapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q3 2026, its #951 holding.
  • DnB Asset Management first reported a position in Protagonist Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 252 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on DnB Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.